不同病因下门静脉血栓的发病机制和治疗进展
Pathogenesis and Therapeutic Advances in Portal Vein Thrombosis under Different Etiologies
DOI: 10.12677/acm.2025.1582199, PDF,   
作者: 陈婉婷:湘西自治州人民医院(吉首大学第一附属医院)消化科,湖南 吉首;吉首大学医学院,湖南 吉首;向 群*:湘西自治州人民医院(吉首大学第一附属医院)消化科,湖南 吉首;罗雪梅:吉首大学医学院,湖南 吉首
关键词: 门静脉血栓病因发病机制治疗Portal Vein Thrombosis Etiology Pathogenesis Treatment
摘要: 门静脉血栓是以门静脉主干及其肝内分支血栓形成的重要血管疾病,常伴随肠系膜静脉或脾静脉血栓发生。目前临床主要基于临床症状、严重程度、病因学等建立分类系统,其中病因学分类分为:慢性肝病、恶性肿瘤及特发型门静脉血栓三大类。不同病因下门静脉发病机制独具特征,通过病因精准干预成为门静脉血栓管理的核心策略。当前治疗方式主要涉及传统抗凝和经颈静脉肝内门体分流术等,尤其是门静脉支架置入术及靶向抗凝等新型疗法的突破性进展为治疗门静脉血栓提供了新思路。本文就不同病因下门静脉血栓发病机制及治疗策略的最新进展作一综述。
Abstract: Portal vein thrombosis is an important vascular disease characterized by thrombosis of the main trunk of the portal vein and its intrahepatic branches, which is often accompanied by thrombosis of the mesenteric vein or splenic vein. Currently, a classification system has been established based on clinical symptoms, severity and etiology, among which the etiological classification is divided into three categories: chronic liver disease, malignant tumor and idiopathic portal vein thrombosis. The pathogenesis of portal vein under different etiologies is unique, and precise intervention through etiology has become the core strategy of portal vein thrombosis management. Current treatment modalities mainly involve traditional anticoagulation and transjugular intrahepatic portosystemic shunt, etc. In particular, breakthroughs in new therapies, such as portal stenting and targeted anticoagulation, have provided new ideas for the treatment of portal vein thrombosis. In this article, we summarize the recent advances in the pathogenesis and therapeutic strategies of portal vein thrombosis under different etiologies.
文章引用:陈婉婷, 向群, 罗雪梅. 不同病因下门静脉血栓的发病机制和治疗进展[J]. 临床医学进展, 2025, 15(8): 65-76. https://doi.org/10.12677/acm.2025.1582199

参考文献

[1] 祁兴顺, 杨玲. 肝硬化门静脉血栓管理专家共识(2020年, 上海) [J]. 临床肝胆病杂志, 2020, 36(12): 2667-2674.
[2] Caiano, L.M., Riva, N., Carrier, M., Gatt, A. and Ageno, W. (2022) Treatment of Portal Vein Thrombosis: An Updated Narrative Review. Minerva Medica, 112, 713-725. [Google Scholar] [CrossRef] [PubMed]
[3] Driever, E.G., Magaz, M., Adelmeijer, J., Turon, F., Baiges, A., Olivas, P., et al. (2022) The Portal Vein in Patients with Cirrhosis Is Not an Excessively Inflammatory or Hypercoagulable Vascular Bed, a Prospective Cohort Study. Journal of Thrombosis and Haemostasis, 20, 2075-2082. [Google Scholar] [CrossRef] [PubMed]
[4] Shukla, A. and Giri, S. (2022) Portal Vein Thrombosis in Cirrhosis. Journal of Clinical and Experimental Hepatology, 12, 965-979. [Google Scholar] [CrossRef] [PubMed]
[5] Turon, F., Driever, E.G., Baiges, A., Cerda, E., García-Criado, Á., Gilabert, R., et al. (2021) Predicting Portal Thrombosis in Cirrhosis: A Prospective Study of Clinical, Ultrasonographic and Hemostatic Factors. Journal of Hepatology, 75, 1367-1376. [Google Scholar] [CrossRef] [PubMed]
[6] Praktiknjo, M., Trebicka, J., Carnevale, R., Pastori, D., Queck, A., Ettorre, E., et al. (2020) Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis. Clinical and Translational Gastroenterology, 11, e00123. [Google Scholar] [CrossRef] [PubMed]
[7] Shalaby, S., Simioni, P., Campello, E., Spiezia, L., Gavasso, S., Bizzaro, D., et al. (2020) Endothelial Damage of the Portal Vein Is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. Thrombosis and Haemostasis, 120, 1173-1181. [Google Scholar] [CrossRef] [PubMed]
[8] Poredos, P. and Jezovnik, M.K. (2017) Endothelial Dysfunction and Venous Thrombosis. Angiology, 69, 564-567. [Google Scholar] [CrossRef] [PubMed]
[9] Zifkos, K., Bochenek, M.L., Gogiraju, R., Robert, S., Pedrosa, D., Kiouptsi, K., et al. (2024) Endothelial PTP1B Deletion Promotes VWF Exocytosis and Venous Thromboinflammation. Circulation Research, 134, e93-e111. [Google Scholar] [CrossRef] [PubMed]
[10] Violi, F., Pignatelli, P., Castellani, V., Carnevale, R. and Cammisotto, V. (2023) Gut Dysbiosis, Endotoxemia and Clotting Activation: A Dangerous Trio for Portal Vein Thrombosis in Cirrhosis. Blood Reviews, 57, Article ID: 100998. [Google Scholar] [CrossRef] [PubMed]
[11] Carr, B., Donghia, R. and Yilmaz, S. (2024) Characteristics of HCC Patients with Portal Vein Thrombosis: Albumin and Survival. Oncology, 1-22. [Google Scholar] [CrossRef] [PubMed]
[12] Péré, G., Basselerie, H., Maulat, C., Pitocco, A., Leblanc, P., Philis, A., et al. (2021) Splenic Volume and Splenic Vein Diameter Are Independent Pre-Operative Risk Factors of Portal Vein Thrombosis after Splenectomy: A Retrospective Cohort Study. BMC Surgery, 21, Article No. 366. [Google Scholar] [CrossRef] [PubMed]
[13] de’Angelis, N., Abdalla, S., Lizzi, V., Esposito, F., Genova, P., Roy, L., et al. (2017) Incidence and Predictors of Portal and Splenic Vein Thrombosis after Pure Laparoscopic Splenectomy. Surgery, 162, 1219-1230. [Google Scholar] [CrossRef] [PubMed]
[14] Matsui, T., Usui, M., Wada, H., Iizawa, Y., Kato, H., Tanemura, A., et al. (2017) Platelet Activation Assessed by Glycoprotein Vi/Platelet Ratio Is Associated with Portal Vein Thrombosis after Hepatectomy and Splenectomy in Patients with Liver Cirrhosis. Clinical and Applied Thrombosis/Hemostasis, 24, 254-262. [Google Scholar] [CrossRef] [PubMed]
[15] Li, Y., Fu, X., Li, Y., Liu, P., Liu, S. and Pan, Y. (2022) Early Prevention and Risk Factors Analysis of Portal Vein System Thrombosis after Laparoscopic Splenectomy and Pericardial Devascularization. Surgical Endoscopy, 36, 8918-8926. [Google Scholar] [CrossRef] [PubMed]
[16] Jiang, S., Ai, Y., Ni, L., Wu, L., Huang, X. and Chen, S. (2022) Platelet-Derived TGF-β1 Is Related to Portal Vein Thrombosis in Cirrhosis by Promoting Hypercoagulability and Endothelial Dysfunction. Frontiers in Cardiovascular Medicine, 9, Article 938397. [Google Scholar] [CrossRef] [PubMed]
[17] Lin, Y., Cai, X., Hong, H., Chen, J., Chen, Y. and Du, Q. (2023) Risk Factors of Portal Vein System Thrombosis after Splenectomy: A Meta‐Analysis. ANZ Journal of Surgery, 93, 2806-2819. [Google Scholar] [CrossRef] [PubMed]
[18] Zhao, F., Ding, J., Cui, J., Zhu, M. and Zhao, W. (2023) Platelet Activation Is Upregulated in Cirrhotic Patients with Portal Vein Thrombosis. Thrombosis and Haemostasis, 124, 739-752. [Google Scholar] [CrossRef] [PubMed]
[19] Swinson, B., Waters, P.S., Webber, L., Nathanson, L., Cavallucci, D.J., O’Rourke, N., et al. (2021) Portal Vein Thrombosis Following Elective Laparoscopic Splenectomy: Incidence and Analysis of Risk Factors. Surgical Endoscopy, 36, 3332-3339. [Google Scholar] [CrossRef] [PubMed]
[20] Cheng, Z., Yu, F., Tian, J., Guo, P., Li, J., Chen, J., et al. (2015) A Comparative Study of Two Anti-Coagulation Plans on the Prevention of PVST after Laparoscopic Splenectomy and Esophagogastric Devascularization. Journal of Thrombosis and Thrombolysis, 40, 294-301. [Google Scholar] [CrossRef] [PubMed]
[21] Benito-González, T. and Estévez-Loureiro, R. (2016) Mean Platelet Volume: Ready for Prime Time? Journal of Thoracic Disease, 8, E1481-E1483. [Google Scholar] [CrossRef] [PubMed]
[22] Blair, T.A. and Frelinger, A.L. (2019) Platelet Surface Marker Analysis by Mass Cytometry. Platelets, 31, 633-640. [Google Scholar] [CrossRef] [PubMed]
[23] He, S. and He, F. (2015) Predictive Model of Portal Venous System Thrombosis in Cirrhotic Portal Hypertensive Patients after Splenectomy. International Journal of Clinical and Experimental Medicine, 8, 4236-4242.
[24] 刘军, 胡洪生, 吴红伟, 等. VEGF在门静脉高压患者术后门静脉系统血栓形成过程中的表达及意义[J]. 中国普外基础与临床杂志, 2021, 28(1): 63-66.
[25] Zhang, S., Li, Y., Zhang, J., Sun, Y., Chu, X., Gui, X., et al. (2023) Platelet-Derived TGF-β1 Promotes Deep Vein Thrombosis. Thrombosis and Haemostasis, 124, 641-648. [Google Scholar] [CrossRef] [PubMed]
[26] Senzolo, M., Garcia-Tsao, G. and García-Pagán, J.C. (2021) Current Knowledge and Management of Portal Vein Thrombosis in Cirrhosis. Journal of Hepatology, 75, 442-453. [Google Scholar] [CrossRef] [PubMed]
[27] 李宝定, 卜阳, 田明国, 等. 脾切除联合贲门周围血管离断术后门静脉系统血栓发生率及其防治[J]. 肝胆胰外科杂志, 2022, 34(1): 19-22, 29.
[28] Pavel, V., Scharf, G., Mester, P., Krauss, L.U., Gülow, K., Mehrl, A., et al. (2023) Partial Splenic Embolization as a Rescue and Emergency Treatment for Portal Hypertension and Gastroesophageal Variceal Hemorrhage. BMC Gastroenterology, 23, Article No. 180. [Google Scholar] [CrossRef] [PubMed]
[29] Ogawa, S., Yamamoto, A., Jogo, A., Nakano, M.M., Kageyama, K., Sohgawa, E., et al. (2021) Splenic Vein Diameter Is a Risk Factor for the Portal Venous System Thrombosis after Partial Splenic Artery Embolization. CardioVascular and Interventional Radiology, 44, 921-930. [Google Scholar] [CrossRef] [PubMed]
[30] Ueda, J., Mamada, Y., Taniai, N., Yoshioka, M., Matsushita, A., Mizutani, S., et al. (2023) Evaluation of Splenic Infarction Ratio and Platelet Increase Ratio after Partial Splenic Artery Embolization. Journal of International Medical Research, 51. [Google Scholar] [CrossRef] [PubMed]
[31] Cohen, O., Caiano, L.M., Tufano, A. and Ageno, W. (2021) Cancer-Associated Splanchnic Vein Thrombosis. Seminars in Thrombosis and Hemostasis, 47, 931-941. [Google Scholar] [CrossRef] [PubMed]
[32] Elkrief, L., Payancé, A., Plessier, A., d’Alteroche, L., Ronot, M., Paradis, V., et al. (2023) Management of Splanchnic Vein Thrombosis. JHEP Reports, 5, Article ID: 100667. [Google Scholar] [CrossRef] [PubMed]
[33] Luque Paz, D., Kralovics, R. and Skoda, R.C. (2023) Genetic Basis and Molecular Profiling in Myeloproliferative Neoplasms. Blood, 141, 1909-1921. [Google Scholar] [CrossRef] [PubMed]
[34] Álvarez-Reguera, C., Prieto-Peña, D., Herrero-Morant, A., Sánchez-Bilbao, L., Batlle-López, A., Fernández-Luis, S., et al. (2024) Features of Immune Mediated Diseases in JAK2 (V617F)-Positive Myeloproliferative Neoplasms and the Potential Therapeutic Role of JAK Inhibitors. European Journal of Internal Medicine, 123, 102-106. [Google Scholar] [CrossRef] [PubMed]
[35] Patil, C., Ananthu, V.R., Junaid, M.A.H., Lavanya, P. and Jabeen, S. (2024) JAK2 V617F Mutation Leading to Portal Vein Thrombosis in a Young Patient: A Case Report. Cureus, 16, e76547. [Google Scholar] [CrossRef] [PubMed]
[36] Bade, N.A., Lu, C., Patzke, C.L., Baer, M.R., Duong, V.H., Law, J.Y., et al. (2019) Optimizing Pegylated Asparaginase Use: An Institutional Guideline for Dosing, Monitoring, and Management. Journal of Oncology Pharmacy Practice, 26, 74-92. [Google Scholar] [CrossRef] [PubMed]
[37] Douer, D., Gökbuget, N., Stock, W. and Boissel, N. (2022) Optimizing Use of L-Asparaginase-Based Treatment of Adults with Acute Lymphoblastic Leukemia. Blood Reviews, 53, Article ID: 100908. [Google Scholar] [CrossRef] [PubMed]
[38] Giri, S., Angadi, S., Varghese, J., Sundaram, S. and Bhrugumalla, S. (2023) Prothrombotic States in Portal Vein Thrombosis and Budd-Chiari Syndrome in India: A Systematic Review and Meta-Analysis. Indian Journal of Gastroenterology, 42, 629-641. [Google Scholar] [CrossRef] [PubMed]
[39] Smalberg, J.H., Arends, L.R., Valla, D.C., Kiladjian, J., Janssen, H.L.A. and Leebeek, F.W.G. (2012) Myeloproliferative Neoplasms in Budd-Chiari Syndrome and Portal Vein Thrombosis: A Meta-Analysis. Blood, 120, 4921-4928. [Google Scholar] [CrossRef] [PubMed]
[40] De Broucker, C., Plessier, A., Ollivier-Hourmand, I., Dharancy, S., Bureau, C., Cervoni, J., et al. (2022) Multicenter Study on Recent Portal Venous System Thrombosis Associated with Cytomegalovirus Disease. Journal of Hepatology, 76, 115-122. [Google Scholar] [CrossRef] [PubMed]
[41] Qi, X., De Stefano, V., Su, C., Bai, M., Guo, X. and Fan, D. (2015) Associations of Antiphospholipid Antibodies with Splanchnic Vein Thrombosis: A Systematic Review with Meta-Analysis. Medicine, 94, e496. [Google Scholar] [CrossRef] [PubMed]
[42] You, H., Zhao, J., Huang, C., Tian, X., Li, M. and Zeng, X. (2021) Early Initiation of Anticoagulation Improves the Long-Term Prognosis in Patients with Antiphospholipid Syndrome Associated Portal Vein Thrombosis. Frontiers in Medicine, 8, Article 630660. [Google Scholar] [CrossRef] [PubMed]
[43] Li, L., Tan, Q., Wu, X., Mou, X., Lin, Z., Liu, T., et al. (2024) Coagulopathy and Acute Pancreatitis: Pathophysiology and Clinical Treatment. Frontiers in Immunology, 15, Article 1477160. [Google Scholar] [CrossRef] [PubMed]
[44] Duceppe, E., Lauzon, J., Galliger, S., Zhang, B., Solomon, H. and Serrano, P.E. (2021) Incidence and Predictors of Splanchnic Vein Thrombosis and Mortality Following Hepatobiliary and Pancreatic Surgery. Journal of Thrombosis and Haemostasis, 19, 797-804. [Google Scholar] [CrossRef] [PubMed]
[45] Valeriani, E., Di Nisio, M., Riva, N., Cohen, O., Garcia-Pagan, J., Magaz, M., et al. (2021) Anticoagulant Therapy for Splanchnic Vein Thrombosis: A Systematic Review and Meta-Analysis. Blood, 137, 1233-1240. [Google Scholar] [CrossRef] [PubMed]
[46] Xiao, X., Zhu, W. and Dai, Q. (2024) Direct Oral Anticoagulants versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review. Clinical and Applied Thrombosis/Hemostasis, 30. [Google Scholar] [CrossRef] [PubMed]
[47] Primignani, M., Tosetti, G. and Ierardi, A.M. (2023) Approach to Different Thrombolysis Techniques and Timing of Thrombolysis in the Management of Portal Vein Thrombosis in Cirrhotic Patients. Journal of Translational Internal Medicine, 11, 198-202. [Google Scholar] [CrossRef] [PubMed]
[48] Ju, C., Li, X., Gadani, S., Kapoor, B. and Partovi, S. (2021) Portal Vein Thrombosis: Diagnosis and Endovascular Management. RöFoFortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 194, 169-180. [Google Scholar] [CrossRef] [PubMed]
[49] Farsad, K. and Zaman, A. (2019) Percutaneous Transmesenteric Portal Vein Recanalization and Transjugular Direct Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Occlusion. Journal of Vascular and Interventional Radiology, 30, 892-893. [Google Scholar] [CrossRef] [PubMed]
[50] Bozon-Rivière, P., Rudler, M., Weiss, N. and Thabut, D. (2025) TIPS and Hepatic Encephalopathy in Patients with Cirrhosis. Metabolic Brain Disease, 40, Article No. 117. [Google Scholar] [CrossRef] [PubMed]
[51] Ramalingam, V., Yang, L.M., McCarthy, C.J. and Ahmed, M. (2023) Interventional Approach to Portal Vein Thrombosis and Liver Transplantation: State of the Art. Life, 13, Article 1262. [Google Scholar] [CrossRef] [PubMed]
[52] Park, J.H., Yeo, J.H., Kim, Y.S., Ahn, H.K., Sym, S., Shin, D., et al. (2020) Portal Vein Stent for Symptomatic Malignant Portal Vein Stenosis: A Single-Center Experience. Current Problems in Cancer, 44, Article ID: 100476. [Google Scholar] [CrossRef] [PubMed]
[53] Ju Kim, Y., Jin Yoon, C., Hwan Lee, J., Seok Choi, W., Yoon, Y., Hwang, J., et al. (2022) Transhepatic Stent Placement for Malignant Portal Vein Obstruction: Long Term Efficacy and Factors Associated with Stent Failure. European Journal of Radiology, 149, Article ID: 110230. [Google Scholar] [CrossRef] [PubMed]
[54] Chen, Z., Xie, H., Hu, M., et al. (2020) Recent Progress in Treatment of Hepatocellular Carcinoma. American Journal of Cancer Research, 10, 2993-3036.
[55] Sui, W., Li, J. and Fu, J. (2024) Transarterial Chemoembolization Plus Stent Placement for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Meta-Analysis. World Journal of Clinical Oncology, 15, 447-455. [Google Scholar] [CrossRef] [PubMed]
[56] Gawaz, M., Geisler, T. and Borst, O. (2023) Current Concepts and Novel Targets for Antiplatelet Therapy. Nature Reviews Cardiology, 20, 583-599. [Google Scholar] [CrossRef] [PubMed]
[57] Harrington, J., Piccini, J.P., Alexander, J.H., Granger, C.B. and Patel, M.R. (2023) Clinical Evaluation of Factor Xia Inhibitor Drugs. Journal of the American College of Cardiology, 81, 771-779. [Google Scholar] [CrossRef] [PubMed]
[58] Gailani, D. and Gruber, A. (2024) Targeting Factor XI and Factor Xia to Prevent Thrombosis. Blood, 143, 1465-1475. [Google Scholar] [CrossRef] [PubMed]
[59] Zabaleta, N., Unzu, C., Weber, N.D. and Gonzalez-Aseguinolaza, G. (2023) Gene Therapy for Liver Diseases—Progress and Challenges. Nature Reviews Gastroenterology & Hepatology, 20, 288-305. [Google Scholar] [CrossRef] [PubMed]
[60] Samelson-Jones, B.J., Doshi, B.S. and George, L.A. (2024) Coagulation Factor VIII: Biological Basis of Emerging Hemophilia a Therapies. Blood, 144, 2185-2197. [Google Scholar] [CrossRef] [PubMed]
[61] Leebeek, F.W.G. and Miesbach, W. (2021) Gene Therapy for Hemophilia: A Review on Clinical Benefit, Limitations, and Remaining Issues. Blood, 138, 923-931. [Google Scholar] [CrossRef] [PubMed]
[62] Mahlangu, J., Kaczmarek, R., von Drygalski, A., Shapiro, S., Chou, S., Ozelo, M.C., et al. (2023) Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. New England Journal of Medicine, 388, 694-705. [Google Scholar] [CrossRef] [PubMed]
[63] Astermark, J., Buckner, T.W., Frenzel, L., Hatswell, A.J., You, X., Liu, H., et al. (2023) Matching‐Adjusted Indirect Comparison of Bleeding Outcomes in Severe Haemophilia A: Comparing Valoctocogene Roxaparvovec Gene Therapy, Emicizumab Prophylaxis, and FVIII Replacement Prophylaxis. Haemophilia, 29, 1087-1094. [Google Scholar] [CrossRef] [PubMed]
[64] Mousaei Ghasroldasht, M., Seok, J., Park, H., Liakath Ali, F.B. and Al-Hendy, A. (2022) Stem Cell Therapy: From Idea to Clinical Practice. International Journal of Molecular Sciences, 23, Article 2850. [Google Scholar] [CrossRef] [PubMed]
[65] Karagyaur, M., Dzhauari, S., Basalova, N., Aleksandrushkina, N., Sagaradze, G., Danilova, N., et al. (2021) MSC Secretome as a Promising Tool for Neuroprotection and Neuroregeneration in a Model of Intracerebral Hemorrhage. Pharmaceutics, 13, Article 2031. [Google Scholar] [CrossRef] [PubMed]
[66] Li, S., Li, H., Zhangdi, H., Xu, R., Zhang, X., Liu, J., et al. (2022) Hair Follicle-MSC-Derived Small Extracellular Vesicles as a Novel Remedy for Acute Pancreatitis. Journal of Controlled Release, 352, 1104-1115. [Google Scholar] [CrossRef] [PubMed]
[67] Yang, X., Li, Q., Liu, W., Zong, C., Wei, L., Shi, Y., et al. (2023) Mesenchymal Stromal Cells in Hepatic Fibrosis/Cirrhosis: From Pathogenesis to Treatment. Cellular & Molecular Immunology, 20, 583-599. [Google Scholar] [CrossRef] [PubMed]